{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorder&page=52",
    "query": {
      "condition": "Skin Disorder",
      "page": 52
    },
    "page_size": 10
  },
  "pagination": {
    "page": 52,
    "page_size": 10,
    "total_count": 16122,
    "total_pages": 1613,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorder&page=53&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorder&page=51&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T23:31:55.250Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00588614",
      "title": "High Risk Screening Breast MR Using a Rapid Imaging Exam",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "25 Years to 75 Years · Female only"
      },
      "enrollment_count": 140,
      "start_date": "2006-04",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2012-05-30",
      "last_synced_at": "2026-11-01T23:31:55.250Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00588614"
    },
    {
      "nct_id": "NCT05755347",
      "title": "Assessing Functional Status Needs Via PRO Measures for Pts With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Metastasis"
      ],
      "interventions": [
        {
          "name": "General health survey questionnaires",
          "type": "OTHER"
        },
        {
          "name": "PROMIS Cancer Function Brief 3D profile questionnaires",
          "type": "OTHER"
        },
        {
          "name": "FACT-G questionnaires",
          "type": "OTHER"
        },
        {
          "name": "Godin Leisure-Time Exercise Questionnaire",
          "type": "OTHER"
        },
        {
          "name": "REAP-S questionnaires",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2023-03-17",
      "completion_date": "2024-02-05",
      "has_results": false,
      "last_update_posted_date": "2024-04-11",
      "last_synced_at": "2026-11-01T23:31:55.250Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05755347"
    },
    {
      "nct_id": "NCT04990726",
      "title": "Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Melanoma, Stage II",
        "Melanoma Stage IV"
      ],
      "interventions": [
        {
          "name": "Assessment",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2019-12-05",
      "completion_date": "2027-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-11-01T23:31:55.250Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04990726"
    },
    {
      "nct_id": "NCT06982521",
      "title": "Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "PIK3CA Mutation",
        "HER2- Negative Breast Cancer",
        "Hormone Receptor Positive Tumor",
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Zovegalisib",
          "type": "DRUG"
        },
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Relay Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 540,
      "start_date": "2025-08-26",
      "completion_date": "2031-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-01T23:31:55.250Z",
      "location_count": 52,
      "location_summary": "Gilbert, Arizona • Beverly Hills, California • Duarte, California + 42 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06982521"
    },
    {
      "nct_id": "NCT04883814",
      "title": "18F-fluoroestradiol (FES) PET/CT for Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "18F-fluoroestradiol PET/CT",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Hoag Memorial Hospital Presbyterian",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 124,
      "start_date": "2021-01-15",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-11-01T23:31:55.250Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04883814"
    },
    {
      "nct_id": "NCT02732314",
      "title": "Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dermatitis, Atopic",
        "Eczema"
      ],
      "interventions": [
        {
          "name": "Investigational OTC Cream",
          "type": "DRUG"
        },
        {
          "name": "Cosmetic Eczema Cream",
          "type": "OTHER"
        },
        {
          "name": "0.05% Desonide Cream",
          "type": "DRUG"
        },
        {
          "name": "Placebo Cream",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Procter & Gamble Beauty",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 53,
      "start_date": "2016-03",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-10-05",
      "last_synced_at": "2026-11-01T23:31:55.250Z",
      "location_count": 1,
      "location_summary": "Raleigh, North Carolina",
      "locations": [
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02732314"
    },
    {
      "nct_id": "NCT05907304",
      "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Naporafenib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Erasca, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "12 Years to 99 Years"
      },
      "enrollment_count": 86,
      "start_date": "2023-08-17",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-11-01T23:31:55.250Z",
      "location_count": 14,
      "location_summary": "San Francisco, California • New Haven, Connecticut • Sarasota, Florida + 10 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05907304"
    },
    {
      "nct_id": "NCT01437384",
      "title": "Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Thrombocytopenic Purpura (ITP)"
      ],
      "interventions": [
        {
          "name": "E5501",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2011-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-05-21",
      "last_synced_at": "2026-11-01T23:31:55.250Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01437384"
    },
    {
      "nct_id": "NCT03641755",
      "title": "Olaparib + Sapacitabine in BRCA Mutant Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Sapacitabine",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2018-10-01",
      "completion_date": "2026-10-22",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-11-01T23:31:55.250Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03641755"
    },
    {
      "nct_id": "NCT00650455",
      "title": "Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "valdecoxib",
          "type": "DRUG"
        },
        {
          "name": "naproxen",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 489,
      "start_date": "2003-02",
      "completion_date": "2005-01",
      "has_results": false,
      "last_update_posted_date": "2008-07-21",
      "last_synced_at": "2026-11-01T23:31:55.250Z",
      "location_count": 52,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00650455"
    }
  ]
}